Envveno Medical Corp (NVNO) Stock Price, Quote & News

Company Profile

enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease. The company's lead product is the VenoValve, a replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company also develops e...

Industry: Medical Devices

Sector: Healthcare

Phone: 949 261 2900

Website: www.envveno.com

Address:

70 Doppler, Irvine, United States

haupman Nov. 15 at 12:17 AM

$NVNO now that the VenoValve is dead, that means if the enVVe doesn't go forward, there will be no more dilution because there's nothing to develop. The company can liquidate their cash after settling liabilities and severance. By early next year, that will be roughly $1.05/share.

0 · Reply

BOOGEYMAN_TRADEZ Nov. 15 at 12:14 AM

$NVNO this is what I was thinking

0 · Reply

haupman Nov. 14 at 9:38 PM

$NVNO the soon to be released study for the enVVe is a "heads I win" and "tails I win" scenario at 40 cents. If it's a positive study, the stock can go straight to $1. If it's a negative study, they'll have no choice but to liquidate and the stock still heads straight to $1.

1 · Reply

cohunter9 Nov. 14 at 8:01 PM

$NVNO

0 · Reply

MadHatterTrades74 Nov. 14 at 6:49 PM

$NVNO This may look and seem like a value trading at -4X cash but with that new S-3 $50M press release, this becomes a ticking time bomb. They plan on bypassing the baby shelf rule most likely by making the offering as a private placement. it basically allows them to do one offering for the full $50M and because of this setback with the FDA they will more than likely make the offering at a DEEP discount.(i.e. 166.66M shares @ .30 = $50) $BCTX did this year after year so it happens

1 · Reply

Arthur86 Nov. 14 at 6:14 PM

$NVNO

0 · Reply

BOOGEYMAN_TRADEZ Nov. 14 at 5:39 PM

$NVNO liquidation today would be a huge premium. reaching out to investor relations this weekend - can they at least buy back some of the shares or do a reverse merger? 31.5 Mil cash 8 mil market cap lol.. cash until 2027??

3 · Reply

haupman Nov. 14 at 5:17 PM

$NVNO 12/31 liquidation value is $1. 3/31 liquidation value is $0.80. By the end of the year, it will trade up to the 12/31 liquidation value.

0 · Reply

shaked123 Nov. 14 at 4:56 PM

$NVNO GWT IT BEFORE IT GOES CRAZY

0 · Reply

haupman Nov. 14 at 3:54 PM

$NVNO $1.60 of cash on 9/30 and $1.40 of cash on 12/31 means there are still moves to be made in this stock. Especially with it under 40 cents a double is not out of the questions.

0 · Reply

enVVeno Receives Unfavorable Appeal Decision from the FDA for the VenoValve

Oct 31, 2025, 8:05 AM EDT - 14 days ago

enVVeno Medical Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Sep 26, 2025, 8:45 AM EDT - 7 weeks ago

enVVeno Medical (NASDAQ:NVNO) Participates in Virtual Investor "What This Means" Segment

Sep 15, 2025, 8:45 AM EDT - 2 months ago

enVVeno Medical Updates Regulatory Status of VenoValve(R)

Aug 20, 2025, 7:00 AM EDT - 3 months ago

enVVeno Receives Not-Approvable Letter from the FDA for the VenoValve(R)

Aug 15, 2025, 9:21 AM EDT - 3 months ago

enVVeno Medical to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Aug 6, 2025, 8:30 AM EDT - 3 months ago

Health Economic Study Shows That enVVeno Medical's VenoValve(R) Would be a Cost-Effective Treatment Option for Patients with Severe Chronic Venous Insufficiency

Aug 4, 2025, 9:05 AM EDT - 3 months ago

enVVeno Medical Participates in a New Virtual Investor "What This Means" Segment to Discuss How President Trump's Recent CVI Diagnosis May Impact the Company

Aug 1, 2025, 8:00 AM EDT - 3 months ago

enVVeno Medical Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 22, 2025, 8:45 AM EDT - 4 months ago

enVVeno Medical Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference

Jun 6, 2025, 8:05 AM EDT - 5 months ago

Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting

May 19, 2025, 8:05 AM EDT - 6 months ago

enVVeno Medical Appoints Jennifer Bright as Chief Financial Officer

May 13, 2025, 8:45 AM EDT - 6 months ago

Three-Year VenoValve(R) First-in-Human Trial Data Published in the Annals of Vascular Surgery

May 1, 2025, 8:05 AM EDT - 7 months ago

enVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in 2H24

Apr 23, 2025, 8:00 AM EDT - 7 months ago

VenoValve to be Featured During Presentation at the 47th Annual Charing Cross Symposium

Apr 16, 2025, 8:30 AM EDT - 7 months ago

enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment

Mar 31, 2025, 9:00 AM EDT - 8 months ago

The Impact of the VenoValve(R) on Patients with Primary and Secondary Chronic Venous Insufficiency (CVI) to be Presented at the Society for Clinical Vascular Surgery 52nd Annual Symposium

Feb 28, 2025, 8:00 AM EST - 9 months ago

enVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25

Feb 19, 2025, 9:00 AM EST - 9 months ago

enVVeno Medical Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 19, 2025, 8:45 AM EST - 9 months ago

One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum

Feb 7, 2025, 9:00 AM EST - 10 months ago

Interim Two-Year Follow-Up Data from the VenoValve(R) U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting

Dec 16, 2024, 8:50 AM EST - 11 months ago

enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe

Nov 27, 2024, 8:30 AM EST - 1 year ago

enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website

Nov 20, 2024, 8:30 AM EST - 1 year ago

enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium

Nov 19, 2024, 8:15 AM EST - 1 year ago

enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval

Sep 24, 2021, 9:00 AM EDT - 4 years ago

Hancock Jaffe to Participate in the Duologue Series Virtual Webinar Hosted by Ladenburg Thalmann

Sep 22, 2021, 7:09 AM EDT - 4 years ago

Hancock Jaffe To Rebrand As enVVeno Medical

Sep 21, 2021, 4:00 PM EDT - 4 years ago

Hancock Jaffe Announces Corporate Rebranding to Reflect Prioritization of its Development Pipeline on Venous Disease Programs

Sep 15, 2021, 8:05 AM EDT - 4 years ago

Hancock Jaffe to Host Corporate Update Conference Call and Webcast on September 21, 2021

Sep 8, 2021, 7:43 PM EDT - 4 years ago

Hancock Jaffe Laboratories: Developing Nature-Mimetic Bioprosthetics

Sep 7, 2021, 8:05 AM EDT - 4 years ago

Hancock Jaffe Laboratories Announces $20 Million Registered Direct Offering Priced At-the-Market Under NASDAQ Rules

Aug 19, 2021, 11:49 AM EDT - 4 years ago

Hancock Jaffe Highlights Two-Year Data For Venous Insufficiency Valve

Aug 19, 2021, 8:00 AM EDT - 4 years ago

Hancock Jaffe Presents New Positive Two-Year VenoValve Data at the Society for Vascular Surgery Annual Meeting

Aug 3, 2021, 8:58 AM EDT - 4 years ago

Hancock Jaffe Stock Surges On FDA Breakthrough Designation For Its Venous Insufficiency Device

Aug 3, 2021, 8:05 AM EDT - 4 years ago

FDA Grants Breakthrough Device Designation Status for Hancock Jaffe's VenoValve

Jul 8, 2021, 9:05 AM EDT - 4 years ago

Hancock Jaffe to Present at the Ladenburg Thalmann 2021 Healthcare Conference

Apr 23, 2021, 12:40 PM EDT - 4 years ago

Hancock Jaffe Principal Investigator Dr. Jorge Hernando Ulloa Presents VenoValve One Year First-In-Human Data at Charing Cross International Symposium

Apr 7, 2021, 1:40 PM EDT - 5 years ago

First U.S. Patent Issues on Hancock Jaffe VenoValve

Apr 5, 2021, 7:30 AM EDT - 5 years ago

Hancock Jaffe Receives IDE Approval To Begin VenoValve U.S. Pivotal Trial

Mar 8, 2021, 8:30 AM EST - 5 years ago

Hancock Jaffe Submits IDE Application to FDA for VenoValve U.S. Pivotal Trial

Jan 12, 2021, 8:30 AM EST - 5 years ago

Hancock Jaffe Concludes Successful VenoValve Pre-IDE Meeting with FDA

Dec 30, 2020, 4:15 PM EST - 5 years ago

Hancock Jaffe Announces Executive Promotions

Dec 21, 2020, 8:30 AM EST - 5 years ago

Hancock Jaffe Deemed Compliant With All NASDAQ Continued Listing Requirements

haupman Nov. 15 at 12:17 AM

0 · Reply

BOOGEYMAN_TRADEZ Nov. 15 at 12:14 AM

$NVNO this is what I was thinking

0 · Reply

haupman Nov. 14 at 9:38 PM

1 · Reply

cohunter9 Nov. 14 at 8:01 PM

$NVNO

0 · Reply

MadHatterTrades74 Nov. 14 at 6:49 PM

1 · Reply

Arthur86 Nov. 14 at 6:14 PM

$NVNO

0 · Reply

BOOGEYMAN_TRADEZ Nov. 14 at 5:39 PM

3 · Reply

haupman Nov. 14 at 5:17 PM

$NVNO 12/31 liquidation value is $1. 3/31 liquidation value is $0.80. By the end of the year, it will trade up to the 12/31 liquidation value.

0 · Reply

shaked123 Nov. 14 at 4:56 PM

$NVNO GWT IT BEFORE IT GOES CRAZY

0 · Reply

haupman Nov. 14 at 3:54 PM

$NVNO $1.60 of cash on 9/30 and $1.40 of cash on 12/31 means there are still moves to be made in this stock. Especially with it under 40 cents a double is not out of the questions.

0 · Reply

stockanalysis_ Nov. 14 at 3:44 PM

Losers Today: $ONEG $NVVE $NVNO $TSSI $AVXL Bookmark this page: https://stockanalysis.com/markets/losers/?ref=saveontrading

0 · Reply

UgoGreg Nov. 14 at 3:42 PM

$NVNO https://youtu.be/QhaxxFgb9mU

0 · Reply

topstockalerts Nov. 14 at 3:33 PM

enVVeno Medical Corp shares fell premarket Friday after the FDA upheld its previous non-approval letter for the VenoValve device, designed to treat severe chronic deep venous insufficiency. The agency stated the surgical venous replacement valve did not meet standards for “reasonable assurance of safety and effectiveness,” denying enVVeno’s appeal of the original rejection. CEO Robert Berman said the company will shift focus to enVVe, its next-generation catheter-based venous replacement valve, now ready for human trials. He noted the FDA decision offered “valuable insight” into approval criteria for the new device. The company reported $31.5 million in cash and investments at the end of Q3, with a quarterly burn rate of $4–5 million, expected to fund operations through 2027 during the strategic pivot. $NVNO

0 · Reply

Icemanja Nov. 14 at 3:19 PM

$NVNO IP for EnVVe is WORTHLESS. Cook Medical was 100% correct, a stand alone Valve is not the cure for CVI either surgical or non surgical. They had a extremely hard time getting any institutional funding for Veno Valve. With the miss trust they created its , OVER. Lets all remember on there account the trial was a grand slam success.

0 · Reply

Super_Marioo Nov. 14 at 3:16 PM

$NVNO - glad I took my small profits on this one. trade was just a dead cat bounce as I knew they would get a delisting notice and odds was their appeal would not be successful as you can’t fight a trail failure.

0 · Reply

synaphai Nov. 14 at 3:05 PM

$NVNO Berman is the worst kind of CEO: Incompetent but can sound very reasonable on calls and in interviews. I got out with a loss a year ago but appreciate the lesson learned.

2 · Reply

BigGreenCandle Nov. 14 at 2:10 PM

$NVNO What an unfortunate scam this was. Wait until it goes OTC to 0.000001 per share, then get in for that 'buy and hold'.

0 · Reply

stockanalysis_ Nov. 14 at 2:05 PM

Premarket Losers: $NWGL $GAUZ $AVXL $TSSI $NVNO Bookmark this page: https://stockanalysis.com/markets/premarket/losers/?ref=saveontrading

0 · Reply

longshot45 Nov. 14 at 1:35 PM

$NVNO Sorry to all longs out there. Though I did warn you that the appeal had less than 10% chance of success. In any event CEO and BOD should be removed asap and company dissolved. Sadly thats not how it works and the parasites will drain every ounce of cash they have left before shuttering the doors. Sad end to this story

0 · Reply

OpenOutcrier Nov. 14 at 1:32 PM

$NVNO (-33.8% pre) enVVeno Medical (NASDAQ: NVNO): FDA upholds VenoValve PMA not-approvable on appeal https://ooc.bz/l/84559

0 · Reply

PLEBTRADER Nov. 14 at 11:24 AM

$NVNO the End

0 · Reply

haupman Nov. 14 at 11:10 AM

$NVNO liquidation value is $1.10 right now. The right thing to do would be to wind down operations, pay out the liquidation value and attempt to firesale the remaining tech for additional value. But we know Berman won't do that.

0 · Reply

Market Cap	13.20M
Revenue (ttm)	0.00
Net Income (ttm)	-21.82M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	5,664,500
Avg Vol	554,406
Day's Range	N/A - N/A
Shares Out	20.22M
Stochastic %K	17%
Beta	0.86
Analysts	Hold
Price Target	$12.50